8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 23, 2026·SEC
BioAtla, Inc.(BCAB)Earnings, Financials & Key Ratios
BCAB•NASDAQ
$4.50
$5M mkt cap·Price updated May 6, 2026
AboutBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Show more
- Revenue$2M-81.8%
- EBITDA-$59M+19.3%
- Net Income-$60M+14.6%
- EPS (Diluted)-50.50+29.9%
- Gross Margin100%+9.2%
- EBITDA Margin-2946.6%-343.9%
- Operating Margin-2965.25%-341.1%
- Net Margin-2980.35%-369.8%
BCAB Key Insights
BioAtla, Inc. (BCAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 36.1%
✗Weaknesses
- ✗Profits declining 10.7% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 21.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BCAB Price & Volume
BioAtla, Inc. (BCAB) stock price & volume — 10-year historical chart
Loading chart...
BCAB Growth Metrics
BioAtla, Inc. (BCAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years36.06%
3 Years-
TTM-81.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.86%
Return on Capital
10 Years-157.68%
5 Years-138.7%
3 Years-200.3%
Last Year-398.18%
BCAB Recent Earnings
BioAtla, Inc. (BCAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
Mar 31, 2026EPS
$8.00
Est $12.00
+33.3%
Revenue
$2M
Est $700,000
+185.7%
Q4 2025
Nov 13, 2025EPS
$0.27
Est $0.31
+12.9%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.31
Est $0.29
-6.9%
Revenue
—
Q2 2025
May 6, 2025EPS
$0.29
Est $0.28
-3.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $8.00vs $12.00+33.3% | $2Mvs $700,000+185.7% |
| Q4 2025 | Nov 13, 2025 | $0.27vs $0.31+12.9% | — |
| Q3 2025 | Aug 7, 2025 | $0.31vs $0.29-6.9% | — |
| Q2 2025 | May 6, 2025 | $0.29vs $0.28-3.6% | — |
Based on last 12 quarters of dataView full earnings history →
BCAB Peer Comparison
BioAtla, Inc. (BCAB) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 MIRM | 5.53B | 110.08 | -234.21 | 54.74% | -194.97% | -289.33% | 1.02 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 |
Compare BCAB vs Peers
BioAtla, Inc. (BCAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCAB Income Statement
BioAtla, Inc. (BCAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.63M | 5.2M | 429K | 250K | 0 | 0 | 11M | 2M |
| Revenue Growth % | - | -51.07% | -91.75% | -41.72% | -100% | - | - | -81.82% |
| Cost of Goods Sold | 26.3M | 25.92M | 19.93M | 0 | 1.2M | 1.22M | 925K | 0 |
| COGS % of Revenue | 247.53% | 498.44% | 4646.39% | - | - | - | 8.41% | - |
| Gross Profit | -15.68M▲ 0% | -20.72M▼ 32.2% | -19.5M▲ 5.9% | 250K▲ 101.3% | -1.2M▼ 579.6% | -1.22M▼ 1.8% | 10.07M▲ 925.1% | 2M▼ 80.1% |
| Gross Margin % | -147.53% | -398.44% | -4546.39% | 100% | - | - | 91.59% | 100% |
| Gross Profit Growth % | - | -32.15% | 5.86% | 101.28% | -579.6% | -1.83% | 925.14% | -80.15% |
| Operating Expenses | 38.86M | 7.55M | 10.6M | 96.69M | 106.94M | 128.47M | 84.02M | 61.3M |
| OpEx % of Revenue | 365.68% | 145.17% | 2469.7% | 38676% | - | - | 763.8% | 3065.25% |
| Selling, General & Admin | 12.56M | 7.55M | 10.6M | 38.42M | 28.79M | 25.96M | 21.85M | 17.73M |
| SG&A % of Revenue | 118.15% | 145.17% | 2469.7% | 15366.4% | - | - | 198.62% | 886.6% |
| Research & Development | 26.3M | 25.92M | 19.93M | 58.27M | 79.35M | 103.73M | 63.09M | 43.57M |
| R&D % of Revenue | 247.53% | 498.44% | 4646.39% | 23309.6% | - | - | 573.59% | 2178.65% |
| Other Operating Expenses | -5K | -25.92M | -19.93M | 0 | -1.2M | -1.22M | -925K | 0 |
| Operating Income | -28.23M▲ 0% | -28.27M▼ 0.1% | -30.1M▼ 6.5% | -96.44M▼ 220.4% | -108.14M▼ 12.1% | -129.69M▼ 19.9% | -73.94M▲ 43.0% | -59.3M▲ 19.8% |
| Operating Margin % | -265.68% | -543.62% | -7016.08% | -38576% | - | - | -672.21% | -2965.25% |
| Operating Income Growth % | - | -0.12% | -6.48% | -220.41% | -12.13% | -19.93% | 42.98% | 19.8% |
| EBITDA | -27.44M | -27.41M | -29.09M | -95.11M | -106.94M | -128.47M | -73.02M | -58.93M |
| EBITDA Margin % | -258.21% | -527.08% | -6781.12% | -38044% | - | - | -663.8% | -2946.6% |
| EBITDA Growth % | - | 0.12% | -6.14% | -226.94% | -12.44% | -20.13% | 43.16% | 19.29% |
| D&A (Non-Cash Add-back) | 794K | 860K | 1.01M | 1.33M | 1.2M | 1.22M | 925K | 373K |
| EBIT | -28.03M | -28.27M | -34.46M | -95.4M | -106.48M | -123.46M | -73.94M | -59.3M |
| Net Interest Income | -740K | -1.5M | -1.29M | 347K | 1.65M | 6.31M | 3.37M | 843K |
| Interest Income | 209K | 128K | 100K | 350K | 1.65M | 6.31M | 3.37M | 843K |
| Interest Expense | 949K | 1.63M | 1.39M | 3K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -745K | -1.59M | -5.75M | 1.04M | 1.66M | 6.22M | 4.17M | -302K |
| Pretax Income | -28.98M▲ 0% | -29.86M▼ 3.0% | -35.85M▼ 20.1% | -95.4M▼ 166.1% | -106.48M▼ 11.6% | -123.46M▼ 15.9% | -69.78M▲ 43.5% | -59.61M▲ 14.6% |
| Pretax Margin % | -272.69% | -574.13% | -8357.34% | -38160.8% | - | - | -634.33% | -2980.35% |
| Income Tax | 204K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.7% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -28.98M▲ 0% | -29.79M▼ 2.8% | -35.85M▼ 20.3% | -95.4M▼ 166.1% | -105.28M▼ 10.4% | -123.46M▼ 17.3% | -69.78M▲ 43.5% | -59.61M▲ 14.6% |
| Net Margin % | -272.69% | -572.96% | -8357.34% | -38160.8% | - | - | -634.33% | -2980.35% |
| Net Income Growth % | - | -2.81% | -20.34% | -166.09% | -10.36% | -17.27% | 43.48% | 14.57% |
| Net Income (Continuing) | -28.98M | -29.86M | -35.85M | -95.4M | -106.48M | -123.46M | -69.78M | -59.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 19K | -47K | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -67.00▲ 0% | -46.50▲ 30.6% | -53.00▼ 14.0% | -138.00▼ 160.4% | -137.00▲ 0.7% | -129.00▲ 5.8% | -72.00▲ 44.2% | -50.50▲ 29.9% |
| EPS Growth % | - | 30.6% | -13.98% | -160.38% | 0.72% | 5.84% | 44.19% | 29.86% |
| EPS (Basic) | -67.00 | -46.50 | -53.00 | -138.00 | -137.00 | -129.00 | -72.00 | -50.50 |
| Diluted Shares Outstanding | 431.77K | 673.27K | 673.27K | 691.23K | 778.54K | 955.55K | 971.47K | 1.18M |
| Basic Shares Outstanding | 431.77K | 673.27K | 673.27K | 691.23K | 778.54K | 955.55K | 971.47K | 1.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
BCAB Balance Sheet
BioAtla, Inc. (BCAB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.66M | 4.51M | 240.68M | 247.29M | 220.43M | 116.41M | 51.23M | 8.01M |
| Cash & Short-Term Investments | 10.86M | 3.7M | 238.6M | 244.98M | 215.51M | 111.47M | 49.05M | 7.12M |
| Cash Only | 10.86M | 3.7M | 238.6M | 244.98M | 215.51M | 111.47M | 49.05M | 7.12M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 281K | 214K | 72K | 1.81M | 539K | 320K | 447K | 895K |
| Total Non-Current Assets | 3.98M | 4.83M | 4.26M | 7.13M | 5.3M | 3.25M | 1.19M | 5.82M |
| Property, Plant & Equipment | 3.88M | 4.67M | 4.1M | 6.98M | 5.15M | 3.1M | 1.19M | 5.65M |
| Fixed Asset Turnover | 2.74x | 1.11x | 0.10x | 0.04x | - | - | 9.24x | 0.35x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 97K | 154K | 154K | 154K | 154K | 154K | 0 | 163K |
| Total Assets | 16.64M▲ 0% | 9.34M▼ 43.9% | 244.94M▲ 2523.6% | 254.42M▲ 3.9% | 225.74M▼ 11.3% | 119.66M▼ 47.0% | 52.42M▼ 56.2% | 13.83M▼ 73.6% |
| Asset Turnover | 0.64x | 0.56x | 0.00x | 0.00x | - | - | 0.21x | 0.14x |
| Asset Growth % | - | -43.88% | 2523.58% | 3.87% | -11.28% | -46.99% | -56.19% | -73.62% |
| Total Current Liabilities | 9.2M | 26.72M | 32.26M | 19.81M | 23.13M | 28.34M | 14.54M | 21.92M |
| Accounts Payable | 1.96M | 5.14M | 2.46M | 1.18M | 4.23M | 3.82M | 1.9M | 8.19M |
| Days Payables Outstanding | 27.21 | 72.37 | 44.97 | - | 1.29K | 1.14K | 750.52 | - |
| Short-Term Debt | 0 | 9.71M | 0 | 0 | 0 | 0 | 0 | 1.43M |
| Deferred Revenue (Current) | 169K | 1.42M | 19.81M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.2M | 8.16M | 3.19M | 0 | 13.93M | 19.11M | 11.8M | 12.3M |
| Current Ratio | 1.38x | 0.17x | 7.46x | 12.48x | 9.53x | 4.11x | 3.52x | 0.37x |
| Quick Ratio | 1.38x | 0.17x | 7.46x | 12.48x | 9.53x | 4.11x | 3.52x | 0.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.89M | 38.63M | 2.7M | 23.79M | 22.27M | 20.64M | 23.62M | 28.09M |
| Long-Term Debt | 15M | 8.41M | 682K | 0 | 0 | 0 | 0 | 4.77M |
| Capital Lease Obligations | -4.59M | 0 | 0 | 3.98M | 2.46M | 836K | 0 | 0 |
| Deferred Tax Liabilities | 4.59M | 2.81M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 15.99M | 8.59M | 2.02M | 19.81M | 19.81M | 19.81M | 23.62M | 23.32M |
| Total Liabilities | 45.08M | 65.35M | 34.96M | 43.6M | 45.4M | 48.99M | 38.16M | 50.02M |
| Total Debt | 15M | 18.12M | 682K | 5.37M | 3.98M | 2.46M | 836K | 6.2M |
| Net Debt | 4.14M | 14.42M | -237.92M | -239.61M | -211.53M | -109.01M | -48.21M | -918K |
| Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.03x | 0.06x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -29.54x | -17.34x | -24.81x | -31799.67x | - | - | - | - |
| Total Equity | -28.45M▲ 0% | -56.01M▼ 96.9% | 209.97M▲ 474.9% | 210.82M▲ 0.4% | 180.34M▼ 14.5% | 70.67M▼ 60.8% | 14.27M▼ 79.8% | -36.19M▼ 353.7% |
| Equity Growth % | - | -96.9% | 474.88% | 0.4% | -14.46% | -60.81% | -79.82% | -353.69% |
| Book Value per Share | -65.88 | -83.19 | 311.87 | 305.00 | 231.64 | 73.96 | 14.68 | -30.76 |
| Total Shareholders' Equity | -28.46M | -55.96M | 209.97M | 210.82M | 180.34M | 70.67M | 14.27M | -36.19M |
| Common Stock | 750K | 750K | 3K | 4K | 5K | 5K | 6K | 6K |
| Retained Earnings | -118.56M | -148.35M | -90.92M | -186.32M | -292.8M | -416.26M | -486.04M | -545.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 19K | -47K | 0 | 0 | 0 | 0 | 0 | 0 |
BCAB Cash Flow Statement
BioAtla, Inc. (BCAB) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -35.32M | -9.64M | -36.33M | -62.21M | -90.42M | -104.02M | -71.94M | -48.2M |
| Operating CF Margin % | -332.33% | -185.48% | -8469.46% | -24885.6% | - | - | -653.96% | -2410.2% |
| Operating CF Growth % | - | 72.69% | -276.71% | -71.23% | -45.34% | -15.04% | 30.84% | 32.99% |
| Net Income | -28.98M | -29.86M | -35.85M | -95.4M | -106.48M | -123.46M | -69.78M | -59.61M |
| Depreciation & Amortization | 794K | 860K | 1.01M | 1.33M | 1.2M | 1.22M | 925K | 373K |
| Stock-Based Compensation | 2.64K | -6.4K | 3.02M | 25.12M | 14.56M | 13.54M | 8.92M | 5.43M |
| Deferred Taxes | 0 | 6.4K | 4.46M | -686K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.57M | -5.75M | -6.48M | 3K | 13K | 2K | -807K | 1.32M |
| Working Capital Changes | -9.7M | 25.1M | -2.5M | 7.42M | 287K | 4.68M | -11.2M | 4.28M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 446K | 3.13M | -1.66M | 7.99M | 3.41M | 5.28M | -13.46M | 0 |
| Cash from Investing | -988K | -1.51M | -590K | -924K | -265K | -98K | 0 | 0 |
| Capital Expenditures | -988K | -1.51M | -590K | -924K | -268K | -98K | 0 | 0 |
| CapEx % of Revenue | 9.3% | 29.02% | 137.53% | 369.6% | - | - | - | - |
| Acquisitions | 19K | -5K | -19K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 5K | 19K | 0 | 3K | 0 | 0 | 0 |
| Cash from Financing | 5.02M | 4M | 271.82M | 69.51M | 61.21M | 77K | 9.51M | 6.28M |
| Debt Issued (Net) | 5M | 4M | 3.43M | 0 | 0 | 0 | 0 | 7.13M |
| Equity Issued (Net) | 0 | 0 | 268.41M | 71.42M | 61.68M | 336K | 9.21M | 100K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 19K | -5K | -19K | -1.91M | -469K | -259K | 296K | -949K |
| Net Change in Cash | -31.29M▲ 0% | -7.16M▲ 77.1% | 234.9M▲ 3381.2% | 6.37M▼ 97.3% | -29.47M▼ 562.4% | -104.04M▼ 253.0% | -62.42M▲ 40.0% | -41.93M▲ 32.8% |
| Free Cash Flow | -36.3M▲ 0% | -11.15M▲ 69.3% | -36.92M▼ 231.0% | -63.14M▼ 71.0% | -90.69M▼ 43.6% | -104.11M▼ 14.8% | -71.94M▲ 30.9% | -48.2M▲ 33.0% |
| FCF Margin % | -341.63% | -214.5% | -8606.99% | -25255.2% | - | - | -653.96% | -2410.2% |
| FCF Growth % | - | 69.28% | -231.04% | -70.99% | -43.63% | -14.8% | 30.91% | 32.99% |
| FCF per Share | -84.08 | -16.57 | -54.84 | -91.34 | -116.48 | -108.96 | -74.05 | -40.97 |
| FCF Conversion (FCF/Net Income) | 1.22x | 0.32x | 1.01x | 0.65x | 0.86x | 0.84x | 1.03x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 67K | 6K | 0 | 0 |
BCAB Key Ratios
BioAtla, Inc. (BCAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -46.57% | -45.34% | -53.83% | -98.37% | -164.3% | - |
| Gross Margin | -147.53% | -398.44% | -4546.39% | 100% | - | - | 91.59% | 100% |
| Net Margin | -272.69% | -572.96% | -8357.34% | -38160.8% | - | - | -634.33% | -2980.35% |
| Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.03x | 0.06x | - |
| Interest Coverage | -29.54x | -17.34x | -24.81x | -31799.67x | - | - | - | - |
| FCF Conversion | 1.22x | 0.32x | 1.01x | 0.65x | 0.86x | 0.84x | 1.03x | 0.81x |
| Revenue Growth | - | -51.07% | -91.75% | -41.72% | -100% | - | - | -81.82% |
BCAB SEC Filings & Documents
BioAtla, Inc. (BCAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCAB Frequently Asked Questions
BioAtla, Inc. (BCAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioAtla, Inc. (BCAB) reported $2.0M in revenue for fiscal year 2025. This represents a 81% decrease from $10.6M in 2018.
BioAtla, Inc. (BCAB) saw revenue decline by 81.8% over the past year.
BioAtla, Inc. (BCAB) reported a net loss of $59.6M for fiscal year 2025.
Dividend & Returns
BioAtla, Inc. (BCAB) had negative free cash flow of $34.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More BCAB
BioAtla, Inc. (BCAB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates